Over the past few years, the global enzyme inhibitors market has gained significant traction and is expected to be amongst the fastest-growing therapeutic categories in the pharmaceutical sector. Enzyme inhibitors are molecules that commonly occur in nature and are used as drugs to treat a number of chronic diseases. They interact with enzymes to decrease their activity in order to correct the metabolic imbalance. The increasing demand for effective and accurate drugs is translating into lucrative opportunities for enzyme inhibitors manufacturers. Several companies worldwide are outsourcing manufacturing process to contract manufacturing organizations. This trend is likely to emerge as one of the key trends in the market in the near future.
The report offers an in-depth analysis of drivers, restraints, and opportunities impacting the growth of the global enzyme inhibitors market. For a better understanding, the market has been segmented using various criteria including type and geography. The report also provides a comprehensive study of the competitive landscape and profiles key players along with their contact information, cost and revenue structures, latest developments, and business strategies.
Overview of the Global Enzyme Inhibitors Market
In the recent times, there has been an exponential rise in the incidence of various diseases such as hypertension, cancer, inflammatory, cardiovascular diseases (CVD), infections, and respiratory diseases. Factors such as sedentary lifestyles, unhealthy dietary habits, pandemic threats, excessive consumption of alcohol, and smoking are causing their prevalence to soar. This factor is leading to increasing demand for enzyme inhibitors. Moreover, these inhibitors are also used in the manufacturing of pesticides and herbicides. Therefore, rising agricultural activities across the globe are fuelling the growth of the global enzyme inhibitors market. Another factor driving the market is the rising geriatric population.
However, patent expirations of blockbuster enzyme inhibitors are the paving way for their generic versions. The lower price of generic drugs in comparison with standard drugs is adversely affecting the revenue generation of the overall market. Furthermore, the presence of stringent regulatory norms increases the cost as well as launch period of new drugs, thereby restraining the growth of the global market.
By type, the global enzyme inhibitors market is segmented into irreversible and reversible. Based on geography, the market is categorized into North America, Asia Pacific, Europe, and Rest of the World. The Asia Pacific market for enzyme inhibitors is expected to flourish due to the presence of large patient pool, improving healthcare infrastructure in emerging economies such as India, China, and South Korea, and rapid technological developments in developed countries such as Japan and Australia. Other factors propelling the growth of this regional market are the rising geriatric population and rising per capita expenditure on healthcare.
With the focus shifting towards the development of novel and advanced inhibitors, key players are aggressively trying to enhance their visibility in the global enzyme inhibitors market. Mergers and acquisitions are another important tool for the manufacturers to increase their shares in the market.
Companies Mentioned in the Global Enzyme Inhibitors Market
Some of the key players in the market are AstraZeneca, Merck and Co. Inc., Novartis AG, Pfizer Inc., Ranbaxy Laboratories Ltd, Roche-Genentech Holding Ltd., and Takeda. Other prominent players are Abbott Laboratories Inc., Bayer AG, and Johnson and Johnson Ltd.
This market research report analyzes the following geographies:
- North America
- Asia Pacific
- Rest of the World
This report gives you access to decisive data such as:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years